93P Immunotherapy in advanced/metastatic lung cancer: A real-world study of long-term survivors
Year: 2026
Type: article
Study design: Observational Study
Abstract: Immune checkpoint inhibitors (ICI) improved outcomes in patients with advanced lung cancer. A subset of patients survives beyond two years, being considered long-term survivors. Real-world data focusing on these patients remain limited. We aimed to characterize clinical features, treatment, toxicity and outcomes of long-term survivors with non-small cell lung cancer (NSCLC) advanced/metastatic treated with ICI in a real-world setting.
Source: ESMO Open
Authors: S.C. Fernandes, M.S.C.R. Viana Pereira, P. Fidalgo, M.J.P. de Sousa, S.A.X. Azevedo, R. Romao, A. Araújo
Institutions: Unidade Local de Saúde de Santo António EPE, Hospital Braga
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,910
OpenAlex ID: W7138407377
FWCI:
Cites:
Cited by:
Related to: